Zymeworks Common Stock Stock Probability of Future Stock Price Finishing Over 14.95
| ZYME Stock | USD 14.09 0.33 2.29% |
Zymeworks |
Zymeworks Common Target Price Odds to finish over 14.95
The tendency of Zymeworks Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 14.95 or more in 90 days |
| 14.09 | 90 days | 14.95 | about 15.22 |
Based on a normal probability distribution, the odds of Zymeworks Common to move over $ 14.95 or more in 90 days from now is about 15.22 (This Zymeworks Common Stock probability density function shows the probability of Zymeworks Stock to fall within a particular range of prices over 90 days) . Probability of Zymeworks Common Stock price to stay between its current price of $ 14.09 and $ 14.95 at the end of the 90-day period is about 17.42 .
Given the investment horizon of 90 days Zymeworks Common has a beta of 0.91. This usually means Zymeworks Common Stock market returns are highly-sensitive to returns on the market. As the market goes up or down, Zymeworks Common is expected to follow. Additionally Zymeworks Common Stock has an alpha of 0.2384, implying that it can generate a 0.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Zymeworks Common Price Density |
| Price |
Predictive Modules for Zymeworks Common
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zymeworks Common Stock. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zymeworks Common Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Zymeworks Common is not an exception. The market had few large corrections towards the Zymeworks Common's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zymeworks Common Stock, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zymeworks Common within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 1.49 | |
Ir | Information ratio | 0.08 |
Zymeworks Common Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zymeworks Common for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zymeworks Common Stock can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with profit before overhead, payroll, taxes, and interest of 203.78 M. | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Zymeworks Common has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat |
Zymeworks Common Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zymeworks Stock often depends not only on the future outlook of the current and potential Zymeworks Common's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zymeworks Common's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 68.9 M | |
| Cash And Short Term Investments | 374.3 M |
Zymeworks Common Technical Analysis
Zymeworks Common's future price can be derived by breaking down and analyzing its technical indicators over time. Zymeworks Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Zymeworks Common Stock. In general, you should focus on analyzing Zymeworks Stock price patterns and their correlations with different microeconomic environments and drivers.
Zymeworks Common Predictive Forecast Models
Zymeworks Common's time-series forecasting models is one of many Zymeworks Common's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Zymeworks Common's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Zymeworks Common Stock
Checking the ongoing alerts about Zymeworks Common for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Zymeworks Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with profit before overhead, payroll, taxes, and interest of 203.78 M. | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Zymeworks Common has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat |
Check out Zymeworks Common Backtesting, Zymeworks Common Valuation, Zymeworks Common Correlation, Zymeworks Common Hype Analysis, Zymeworks Common Volatility, Zymeworks Common History as well as Zymeworks Common Performance. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.